Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P20853

UPID:
CP2A7_HUMAN

ALTERNATIVE NAMES:
CYPIIA7; Cytochrome P450 IIA4

ALTERNATIVE UPACC:
P20853; Q13121

BACKGROUND:
The enzyme Cytochrome P450 2A7, with alternative names CYPIIA7 and Cytochrome P450 IIA4, is integral to the body's ability to process a multitude of structurally unrelated compounds. It operates within an NADPH-dependent electron transport pathway in liver microsomes, oxidizing steroids, fatty acids, and xenobiotics.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Cytochrome P450 2A7 holds promise for unveiling novel therapeutic avenues. Its critical involvement in the metabolism of various compounds makes it an attractive target for the development of new drugs, potentially revolutionizing treatment modalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.